LEI 743700W4CQVYAT3WKK38
Herantis Pharma Oyj
Contract awards & public grants
Phase IIa Double-Blind, Placebo- Controlled, Randomized, Efficacy and Safety Study of Subcutaneously Administered HER-096 in Patients with Early-Stage → HERANTIS PHARMA OYJ
European Commission · FI · Grant · 2026-07-08
€4.4M
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease → HERANTIS PHARMA OYJ
European Commission · FI · Grant · 2023-04-07
€2.5M
Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically → HERANTIS PHARMA OYJ
European Commission · FI · Grant · 2016-12-09
€900,000
Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.